Iterion Therapeutics https://iteriontherapeutics.com/ Tue, 31 Mar 2026 23:45:42 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://iteriontherapeutics.com/wp-content/uploads/2023/09/cropped-Asset-1-32x32.png Iterion Therapeutics https://iteriontherapeutics.com/ 32 32 Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed https://www.prnewswire.com/news-releases/iterion-therapeutics-expands-clinical-development-of-tegavivint-a-first-in-class-wnt-catenin-inhibitor-into-colorectal-cancer-with-first-patient-dosed-302724330.html#new_tab Tue, 31 Mar 2026 23:44:39 +0000 https://iteriontherapeutics.com/?p=2021 Tegavivint Targets the Central Oncogenic Driver in Colorectal Cancer as First-in-Class Clinical-Stage Wnt/β-Catenin Inhibitor CRC Expansion Builds on Promising Monotherapy Activity and Favorable Safety Profile Observed in Advanced Hepatocellular Carcinoma HOUSTON, March 25, 2026 /PRNewswire/ — Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to advancing the treatment of Wnt-driven cancers, today reported that the first patient has been …

Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed Read More »

The post Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed appeared first on Iterion Therapeutics.

]]> Tegavivint Targets the Central Oncogenic Driver in Colorectal Cancer as First-in-Class Clinical-Stage Wnt/β-Catenin Inhibitor

CRC Expansion Builds on Promising Monotherapy Activity and Favorable Safety Profile Observed in Advanced Hepatocellular Carcinoma

HOUSTON, March 25, 2026 /PRNewswire/ — Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to advancing the treatment of Wnt-driven cancers, today reported that the first patient has been dosed at HonorHealth Research Institute in a phase 1/2 clinical trial (NCT07463599) evaluating tegavivint, a first-in-class, small molecule inhibitor of the Wnt/β-catenin pathway, for the treatment of metastatic colorectal cancer (mCRC). This milestone expands Iterion’s clinical development into mCRC, a disease with significant unmet need and limited progress in developing targeted therapies.

The post Iterion Therapeutics Expands Clinical Development of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, into Colorectal Cancer with First Patient Dosed appeared first on Iterion Therapeutics.

]]> Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-first-patient-dosed-in-clinical-study-of-tegavivint-a-first-in-class-wnt-catenin-inhibitor-in-relapsedrefractory-osteosarcoma-302683289.html#new_tab Tue, 10 Feb 2026 20:26:42 +0000 https://iteriontherapeutics.com/?p=2007 Tegavivint Is the First Wnt/β-Catenin Inhibitor to Demonstrate Tolerability and Monotherapy Clinical Activity in Complex Solid Tumors Osteosarcoma Program Builds on Clinical Benefit observed in Lead Indication of Advanced Hepatocellular Carcinoma HOUSTON, Feb. 10, 2026 /PRNewswire/ — Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to revolutionizing the treatment of Wnt-driven cancers, today announced that the first patient has …

Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma Read More »

The post Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma appeared first on Iterion Therapeutics.

]]> Tegavivint Is the First Wnt/β-Catenin Inhibitor to Demonstrate Tolerability and Monotherapy Clinical Activity in Complex Solid Tumors

Osteosarcoma Program Builds on Clinical Benefit observed in Lead Indication of Advanced Hepatocellular Carcinoma

HOUSTON, Feb. 10, 2026 /PRNewswire/ — Iterion Therapeutics, a clinical-stage, biopharmaceutical company dedicated to revolutionizing the treatment of Wnt-driven cancers, today announced that the first patient has been dosed in a clinical study evaluating tegavivint, a first-in-class inhibitor of the Wnt/β-catenin pathway, in combination with gemcitabine for patients with relapsed or refractory osteosarcoma. The trial is sponsored by Emory University, conducted at the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and supported by funding from the Peach Bowl LegACy Fund, reflecting strong academic, clinical and philanthropic commitment to advancing new therapies for this rare pediatric cancer.

The post Iterion Therapeutics Announces First Patient Dosed in Clinical Study of Tegavivint, a First-in-Class Wnt/β-Catenin Inhibitor, in Relapsed/Refractory Osteosarcoma appeared first on Iterion Therapeutics.

]]> Iterion to present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics https://iteriontherapeutics.com/iterion-to-present-at-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics/ Thu, 16 Oct 2025 17:49:48 +0000 https://iteriontherapeutics.com/?p=1945 Iterion is excited to present new data on Tegavivint at the upcoming AACR–NCI–EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22–25 in Boston. Our Chief Scientific Officer, Stephen Horrigan, and Senior Director of Translational Research and Non-Clinical Development, Aundrietta Duncan, will share findings highlighting Tegavivint’s first-in-class mechanism and activity in advanced hepatocellular carcinoma (aHCC). Tegavivint, …

Iterion to present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read More »

The post Iterion to present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics appeared first on Iterion Therapeutics.

]]> Iterion is excited to present new data on Tegavivint at the upcoming AACR–NCI–EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22–25 in Boston.

Our Chief Scientific Officer, Stephen Horrigan, and Senior Director of Translational Research and Non-Clinical Development, Aundrietta Duncan, will share findings highlighting Tegavivint’s first-in-class mechanism and activity in advanced hepatocellular carcinoma (aHCC).

Tegavivint, the most advanced Wnt/β-catenin inhibitor in clinical development, targets TBL1, leading to degradation of nuclear β-catenin and inhibition of Wnt-driven oncogenic transcription. This novel approach has shown excellent tolerability and encouraging clinical activity in an ongoing Phase 1/2 aHCC trial.

📍 Poster Details
Title: Activity of Tegavivint in Hepatocellular Carcinoma with Aberrant Wnt/β-catenin Signaling and Evaluation of Biomarker Response
Date & Time: Friday, October 24, 2025 | 12:30 – 4:00 PM
Session: Poster Session B
Poster #: B135

The post Iterion to present at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics appeared first on Iterion Therapeutics.

]]> Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-first-patient-dosed-in-phase-1b2a-clinical-trial-of-tegavivint-in-patients-with-advanced-hepatocellular-carcinoma-who-have-failed-one-or-more-systemic-treatments-302065477.html?tc=eml_cleartime#new_tab Tue, 20 Feb 2024 20:21:55 +0000 https://iteriontherapeutics.com/?p=1882 HOUSTON, Feb. 20, 2024 /PRNewswire/ — Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like protein 1 (TBL1), a downstream target in the Wnt/beta-catenin signaling pathway, announced today it is actively enrolling a Phase 1b/2a clinical trial of its lead molecule, tegavivint, in patients with advanced hepatocellular carcinoma (HCC) that have failed at least …

Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments Read More »

The post Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments appeared first on Iterion Therapeutics.

]]> HOUSTON, Feb. 20, 2024 /PRNewswire/ — Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like protein 1 (TBL1), a downstream target in the Wnt/beta-catenin signaling pathway, announced today it is actively enrolling a Phase 1b/2a clinical trial of its lead molecule, tegavivint, in patients with advanced hepatocellular carcinoma (HCC) that have failed at least one line of systemic therapy.

The post Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments appeared first on Iterion Therapeutics.

]]> Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-the-initiation-of-a-phase-1-clinical-trial-for-tegavivint-in-patients-with-c-myc-overexpressing-relapsed-or-refractory-large-b-cell-lymphomas-301825538.html#new_tab https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-the-initiation-of-a-phase-1-clinical-trial-for-tegavivint-in-patients-with-c-myc-overexpressing-relapsed-or-refractory-large-b-cell-lymphomas-301825538.html#new_tab#respond Tue, 16 May 2023 21:23:58 +0000 https://iteriontherapeutics.com/?p=1534 Iterion announces collaboration with Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute.

The post Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas appeared first on Iterion Therapeutics.

]]> Iterion announces collaboration with Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute.

The post Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas appeared first on Iterion Therapeutics.

]]> https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-the-initiation-of-a-phase-1-clinical-trial-for-tegavivint-in-patients-with-c-myc-overexpressing-relapsed-or-refractory-large-b-cell-lymphomas-301825538.html#new_tab/feed/ 0 Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo https://pubmed.ncbi.nlm.nih.gov/35159107/#new_tab https://pubmed.ncbi.nlm.nih.gov/35159107/#new_tab#respond Tue, 14 Feb 2023 02:21:21 +0000 https://iteriontherapeutics.com/?p=1510 Ioanna Savvidou, Tiffany Khong, Sophie Whish, Irena Carmichael, Tara Sepehrizadeh, Sridurga Mithraprabhu, Stephen K Horrigan, Michael de Veer, Andrew Spence

The post Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo appeared first on Iterion Therapeutics.

]]> Ioanna Savvidou, Tiffany Khong, Sophie Whish, Irena Carmichael, Tara Sepehrizadeh, Sridurga Mithraprabhu, Stephen K Horrigan, Michael de Veer, Andrew Spence

The post Combination of Histone Deacetylase Inhibitor Panobinostat (LBH589) with β-Catenin Inhibitor Tegavivint (BC2059) Exerts Significant Anti-Myeloma Activity Both In Vitro and In Vivo appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/35159107/#new_tab/feed/ 0 Iterion Therapeutics Announces Results from Preclinical study of Tegavivint https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-results-from-preclinical-study-of-tegavivint-in-beta-catenin-mutant-hepatocellular-carcinoma-to-be-presented-at-the-34th-eortc-nci-aacr-symposium-2022-301651888.html#:~:text=%22The%20research%20presented%20at%20ENA,previously%20'cold'%20HCC%20tumors.#new_tab https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-results-from-preclinical-study-of-tegavivint-in-beta-catenin-mutant-hepatocellular-carcinoma-to-be-presented-at-the-34th-eortc-nci-aacr-symposium-2022-301651888.html#:~:text=%22The%20research%20presented%20at%20ENA,previously%20'cold'%20HCC%20tumors.#new_tab#respond Tue, 18 Oct 2022 14:00:35 +0000 https://iteriontherapeutics.com/?p=1414 Iterion shares results from collaboration with Cancer Research UK (CRUK)

The post Iterion Therapeutics Announces Results from Preclinical study of Tegavivint appeared first on Iterion Therapeutics.

]]> Iterion shares results from collaboration with Cancer Research UK (CRUK)

The post Iterion Therapeutics Announces Results from Preclinical study of Tegavivint appeared first on Iterion Therapeutics.

]]> https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-results-from-preclinical-study-of-tegavivint-in-beta-catenin-mutant-hepatocellular-carcinoma-to-be-presented-at-the-34th-eortc-nci-aacr-symposium-2022-301651888.html#:~:text=%22The%20research%20presented%20at%20ENA,previously%20'cold'%20HCC%20tumors.#new_tab/feed/ 0 The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt) – Dependent Gene Transcription in Cancer through Disruption of the Transducin B-Like 1-B-Catenin Protein Complex https://pubmed.ncbi.nlm.nih.gov/34006586/#:~:text=Catenin%20Protein%20Complex-,The%20Small%20Molecule%20BC%2D2059%20Inhibits%20Wingless%2FIntegrated%20(Wnt,1%2D%20%CE%B2%2DCatenin%20Protein%20Complex#new_tab https://pubmed.ncbi.nlm.nih.gov/34006586/#:~:text=Catenin%20Protein%20Complex-,The%20Small%20Molecule%20BC%2D2059%20Inhibits%20Wingless%2FIntegrated%20(Wnt,1%2D%20%CE%B2%2DCatenin%20Protein%20Complex#new_tab#respond Mon, 27 Jun 2022 14:57:31 +0000 https://iteriontherapeutics.com/?p=1374 Raffaella Soldi, Tithi Ghosh Halder, Samuel Sampson, Hariprasad Vankayalapati, Alexis Weston, Trason Thode, Kapil N Bhalla, Serina NG, Ryan Rodrigues Del Villar, Kevin Drenner, Mohan R Kaadige, Stephen K Horrigan, Surinder K Batra, Ravi Salgia, Sunil Sharma  

The post The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt) – Dependent Gene Transcription in Cancer through Disruption of the Transducin B-Like 1-B-Catenin Protein Complex appeared first on Iterion Therapeutics.

]]> Raffaella Soldi, Tithi Ghosh Halder, Samuel Sampson, Hariprasad Vankayalapati, Alexis Weston, Trason Thode, Kapil N Bhalla, Serina NG, Ryan Rodrigues Del Villar, Kevin Drenner, Mohan R Kaadige, Stephen K Horrigan, Surinder K Batra, Ravi Salgia, Sunil Sharma

 

The post The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt) – Dependent Gene Transcription in Cancer through Disruption of the Transducin B-Like 1-B-Catenin Protein Complex appeared first on Iterion Therapeutics.

]]> https://pubmed.ncbi.nlm.nih.gov/34006586/#:~:text=Catenin%20Protein%20Complex-,The%20Small%20Molecule%20BC%2D2059%20Inhibits%20Wingless%2FIntegrated%20(Wnt,1%2D%20%CE%B2%2DCatenin%20Protein%20Complex#new_tab/feed/ 0 Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-results-from-phase-1-dose-escalation-study-of-tegavivint-in-desmoid-tumors-to-be-presented-at-the-2022-asco-annual-meeting-301558729.html#new_tab https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-results-from-phase-1-dose-escalation-study-of-tegavivint-in-desmoid-tumors-to-be-presented-at-the-2022-asco-annual-meeting-301558729.html#new_tab#respond Wed, 01 Jun 2022 16:10:55 +0000 https://iteriontherapeutics.com/?p=1363 Results announced from dose escalation study of tegavivint in desmoid tumors.  

The post Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting appeared first on Iterion Therapeutics.

]]> Results announced from dose escalation study of tegavivint in desmoid tumors.

 

The post Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting appeared first on Iterion Therapeutics.

]]> https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-results-from-phase-1-dose-escalation-study-of-tegavivint-in-desmoid-tumors-to-be-presented-at-the-2022-asco-annual-meeting-301558729.html#new_tab/feed/ 0 Iterion Therapeutics Announces Three Posters To Be Presented at AACR 2022 https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-presentation-of-three-posters-involving-research-into-tegavivint-at-the-aacr-2022-annual-meeting-301520693.html#new_tab https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-presentation-of-three-posters-involving-research-into-tegavivint-at-the-aacr-2022-annual-meeting-301520693.html#new_tab#respond Fri, 08 Apr 2022 14:47:22 +0000 https://iteriontherapeutics.com/?p=1357 Iterion Therapeutics announces presentation of three posters involving research into tegavivint at the AACR 2022 Annual Meeting

The post Iterion Therapeutics Announces Three Posters To Be Presented at AACR 2022 appeared first on Iterion Therapeutics.

]]> Iterion Therapeutics announces presentation of three posters involving research into tegavivint at the AACR 2022 Annual Meeting

The post Iterion Therapeutics Announces Three Posters To Be Presented at AACR 2022 appeared first on Iterion Therapeutics.

]]> https://www.prnewswire.com/news-releases/iterion-therapeutics-announces-presentation-of-three-posters-involving-research-into-tegavivint-at-the-aacr-2022-annual-meeting-301520693.html#new_tab/feed/ 0